Introduction {#s1}
============

A significant decrease in sperm counts over the last 50 y has been reported in men from Western countries, and environmental exposures to developing male germ cells have been suggested as one of the potential causes ([@c7]; [@c45]). Human and animal studies have demonstrated that various paternal exposures, including environmental, diet, drug, and psychological stress, can have consequences for the next generation ([@c12]; [@c50]; [@c63]). Besides mutations and effects directly on genomic sequence, such exposures can reach measureable differences in DNA methylation, histone posttranslational modifications and small noncoding RNA expression (reviewed by [@c54]). DNA methylation undergoes well-characterized patterns of erasure and reestablishment during male germ cell development, is unique in sperm as compared with somatic tissue, and is a strong candidate for an epigenetic mark that can be altered, with the resulting epimutations potentially transmitted to the next generation ([@c51]; [@c68]). To accurately determine how different paternal exposures impact the sperm DNA methylome, there is a need to develop more comprehensive and cost-effective approaches to assess the presence and transmissibility of altered DNA methylation in sperm and its impact on the health of future generations.

DNA methylation can affect $\sim 30\,\text{million}$ sites across the human genome ([@c24]), mainly occurring in a 5′-cytosine-phosphate-guanine-3′ (CpG) dinucleotide context. In male germ cells of the fetal testis, DNA methylation is erased in primordial germ cells and then reestablished, including at imprinted genes, in mitotically quiescent prospermatogonia between weeks 11 and 16 of gestation ([@c29]; [@c61]). It is also at this time that a mother's gestational exposure might impact the germ cell epigenome of her male fetus ([@c64]). At puberty, with the resumption of postnatal spermatogenesis, the majority of DNA methylation patterns acquired in prenatal germ cells need to be maintained in dividing spermatogonia, but continuous remodeling also occurs in meiotic spermatocytes and postmeiotic spermatids ([@c28]; [@c51]). Thus, spermatogenesis, taking about 3 months in men, is an ongoing process and, as such, represents a window from puberty onward when the male germ cell epigenome could be susceptible to environmental insults.

Whole genome bisulfite sequencing (WGBS) provides comprehensive coverage of the epigenome. However, WGBS is challenging to adapt to large studies and, to date, only one human sperm WGBS data set of $> 10 \times$ genome-wide CpG coverage has been published ([@c52]). The Illumina® Infinium HumanMethylation450 BeadChip ($450K$) arrays are the most commonly used approach to assess the methylation of human sperm. With this approach, various factors including age ([@c35]), smoking ([@c3]; [@c36]; [@c44]), phthalates ([@c65]), and infertility ([@c5]; [@c34]) have been reported to alter the sperm DNA methylome. However, the $450K$ arrays provide limited coverage of the epigenome and focus on genic and CpG-rich regions. Reduced representation bisulfite sequencing (RRBS), which targets primarily classical CpG islands and other high-GC content sequences, and low coverage unbiased WGBS, were used to examine sperm of men exposed to high-dose folic acid ([@c2]) or dioxin ([@c56]), respectively. These results suggest that intergenic regions and regions of intermediate methylation (20--80%), where distal regulatory regions reside, may be particularly susceptible to paternal exposures. Although the newer Illumina® Infinium MethylationEPIC BeadChip ($850K$) arrays allow assessment of some intergenic and enhancer CpG methylation sites, they are not specifically designed to interrogate the specialized sperm epigenome.

Targeted capture sequencing panels offer an alternative to WGBS, allowing the customization needed to target the sperm epigenome with enrichment of sequences of interest in both genic and intergenic regions. To this end, we recently implemented methylC-capture sequencing (MCC-Seq) for targeted assessment of DNA methylation in a tissue-specific manner ([@c4]). This approach has been particularly useful for the analysis of intermediate levels (20--80%) of methylation, or dynamic sites, that are postulated to be susceptible to environmental exposures ([@c69]). Using this approach, we showed that DNA methylation variation linked to disease traits is enriched within intergenic and enhancer-associated regions, with such regions characterized by intermediate levels of methylation ([@c4]). With sperm possessing unique epigenetic patterns, differing dramatically from those of somatic cells, ascertaining and targeting the susceptible/variable regions of the sperm DNA methylome, in addition to genic regions, would aid in more efficiently assessing the effect of environmental exposures.

The goal of the current study was to identify regions of variable and/or dynamic DNA methylation in human sperm, to use this information to design a customized human sperm methylation capture panel for DNA methylation profiling, and then to test it in sperm samples of men exposed to low or high levels of methyl donors through either perturbations in folate metabolism or high doses of folic acid supplements, respectively. To accomplish this, we first generated a human sperm WGBS data set that differed from the published one ([@c52]) by examining a sperm DNA sample pooled from a wide cross section of 30 men in order to represent common epigenetic diversity. Using the data, we then designed a targeted human sperm-specific MCC-Seq panel. We validated the approach by assessing the impact of the common 5,10-methylenetetrahydrofolate reductase (*MTHFR*) $677C > T$ polymorphism and response of high-dose folic acid supplementation on DNA methylation of human sperm in different cohorts of men. This customized panel can be used to accurately assess sperm DNA methylation profiles at single CpGs, with enriched coverage targeting putative environmentally susceptible sequences in human sperm. Improvements in our ability to examine sperm DNA methylation following different environmental impacts (i.e., toxicants, exposures, stressors) may optimize assessment of the risks associated with alterations to the germline epigenome and the subsequent health of future generations.

Methods {#s2}
=======

Sample Collection {#s2.1}
-----------------

In order to capture/introduce variability in sperm DNA methylation, a group of 39 men, representing diverse subtypes, varying by fertility status, age, smoking status, *MTHFR* genotype, and folic acid use, were selected. Participants were recruited from three Canadian cities. From Toronto, 24 healthy normospermic male participants were recruited from the Canadian Reproductive Assisted Technology (CReATe) fertility clinic and provided a single semen sample. These men were considered fertile given that they had normal sperm parameters ([@c19]) and that the couple presented to the clinic due to known female factor infertility; indeed, 67% (16/24) of the participants had achieved a previous pregnancy. The Toronto samples were chosen to introduce diversity through differing *MTHFR* genotypes, smoking status, and, at least in part, those who had previously fathered children. Twelve men from the Montreal area were selected from the McGill University Reproductive Centre or the OVO Clinic. Although the Montreal participants were normospermic, they were considered idiopathic infertile because their partners had no known causes for female infertility. The 12 individuals from Montreal, after consulting with their andrologists, received high-dose folic acid supplementation ($5\;{mg}/d$), and sperm samples were collected prior to and within 1 week following 6 months of supplementation. These samples were chosen to include differing *MTHFR* genotypes, use of folic acid supplements, and idiopathic infertility. Finally, three additional participants of unknown fertility status were recruited from the Ottawa Fertility Clinic; these men were included due to their advanced age. In all cohorts, semen samples were collected by masturbation following a recommended 3-day minimum of abstinence. Following semen liquefaction (20--30 min at room temperature), an aliquot was taken for sperm counts and the rest of the sample was immediately frozen at $- 80{^\circ}C$. Informed consent was obtained from all participants. The study was approved by all respective research and ethics boards.

DNA Isolation and *MTHFR* Genotyping {#s2.2}
------------------------------------

Sperm were lysed in a buffer containing a final concentration of $150\text{ \ mM}$ Tris, $10\text{ \ mM}$ ethylenediaminetetraacetic acid, $40\text{ \ mM}$ dithiothreitol, $2\;{mg}/{mL}$ proteinase K, and 0.1% sarkosyl detergent and were incubated overnight at 37°C. DNA was then extracted using the QIAamp® DNA Mini kit (Qiagen) according to the manufacturer's protocols. The common single nucleotide polymorphism, *MTHFR* $677C > T$, was genotyped from all sperm DNA samples using polymerase chain reaction (PCR)--restriction fragment length polymorphism, as originally described by Frosst et al. ([@c26]) and detailed by Sener et al. ([@c60]). Briefly, following DNA amplification, a PCR product of $198\text{ \ bp}$ in size is produced. Presence of the *MTHFR* $677C > T$ polymorphism creates a *Hinf I* restriction cut site; when cleaved, this results in fragments of 175 and $23\text{ \ bp}$, that can be visualized through gel electrophoresis.

Bisulfite Pyrosequencing {#s2.3}
------------------------

We screened sperm DNA samples for possible somatic cell contamination through bisulfite pyrosequencing of the imprinting control regions (ICRs) for H19 imprinted maternally expressed transcript (*H19*) and mesoderm-specific transcript (*MEST*), a paternally and maternally methylated imprinted gene, respectively, on all subjects. As well, this technique was used to validate differentially methylated cytosines (DMCs) found to be altered following analysis of human sperm capture sequencing data (see below). Here, primers were designed to overlap the areas where differential methylation was observed (i.e., intron 4 of sterile alpha motif domain containing 11 (*SAMD11*) and an intergenic region). For the validation, pyrosequencing results from five participants from each the *MTHFR 677CC* and *677TT* groups were compared with their associated human sperm capture panel results. The average methylation between genotypes, as well as individual patient's methylation data, was compared with the average/same patient's capture sequencing data.

For all pyrosequencing assays, $500\text{ \ ng}$ of sperm DNA underwent bisulfite conversion with the EpiTect® bisulfite kit (Qiagen) according to the manufacturer's protocol. Bisulfite PCR was conducted using primers (see Excel Table S1) and pyrosequencing was performed as previously described ([@c21]). Briefly, regions of interest were PCR amplified with one of the primers being biotinylated. Capture of the biotinylated strand was performed with streptavidin-coated sepharose beads and washed using the PyroMark® Q24 Vacuum Workstation (Qiagen). A sequencing primer was annealed to the isolated captured template strand and the pyrosequencing reaction was conducted using the PyroMark® Q24 kit (Qiagen) as per the manufacturer's protocol.

For somatic cell contamination, sperm DNA samples were considered not to be contaminated if methylation across all analyzed CpGs in both imprinted genes did not deviate from the expected high levels of methylation for *H19* ($> 90\%$) and low levels for *MEST* ($< 10\%$) ([@c39]). All samples in the current study met the criteria for lack of somatic cell contamination, and thus no sperm DNA samples were excluded ([Table 1](#t1){ref-type="table"}).

###### 

Demographics of participants for the pooled human sperm WGBS (WGBS-Pool) library.

Table 1 has two columns. The first column lists characteristics. The second column lists N, mean plus or minus SD, and or range.

  Characteristics                                      $n$, $\text{mean} \pm \text{SD}$, and/or range
  ---------------------------------------------------- ---------------------------------------------------------------
  Age                                                  
   Mean                                                $41.4 \pm 9.1\; y$
   Range                                               27--61 y
  Imprinted gene methylation                           
   *H19* (mean, range)                                 $97.1 \pm 0.8\%$, $94.5–97.9\%$
   *MEST* (mean, range)                                $4.2 \pm 1.0\%$, $2.7–6.2\%$
  Fertility status[^*a*^](#TF2){ref-type="table-fn"}   
   Fertile                                             21
   Infertile                                           6
   Unknown                                             3
  Sperm counts (million/mL)                            
   Mean                                                $100.8 \pm 95.6$ ($n = 29$)[^*b*^](#TF3){ref-type="table-fn"}
   Range                                               3.8--497.7
  Percentage DFI (%)                                   
   Mean                                                $15.0 \pm 7.1$ ($n = 26$)[^*b*^](#TF3){ref-type="table-fn"}
   Range                                               6.05--30.9
  Smoking status (*n*)                                 
   Smokers                                             6
   Nonsmokers                                          23
   Unknown                                             1
  *MTHFR* genotype (*n*)                               
   *MTHFR CC*                                          13
   *MTHFR CT*                                          2
   *MTHFR TT*                                          15
  High-dose folic acid use \[$5\;{mg}/d$ (*n*)\]       
   Yes                                                 6
   No                                                  24

Note: DFI, DNA fragmentation index; *MTHFR*, methylenetetrahydrofolate reductase; SD, standard deviation; WGBS, whole genome bisulfite sequencing.

A fertile status was determined if participants were normospermic and presented to the clinic due to known female factor infertility (see "Methods" section).

Sperm counts and %DFI were not measured in all individuals due to limited amount of sample available upon collection.

WGBS and Targeted Capture Sequencing {#s2.4}
------------------------------------

WGBS and targeted bisulfite sequencing were performed as previously described ([@c4]; [@c17]). To examine the variability in human sperm DNA methylation, a subset of the men (total 30 participants; [Table 1](#t1){ref-type="table"}) was chosen in order to produce a single WGBS library pool (WGBS-Pool). A subset of the total of 39 men was chosen in order to ensure sufficient depth of sequencing from all participants in the single WGBS library. More specifically, samples (total $n = 30$) were chosen to reflect differing *MTHFR* genotypes and smoking status from the Toronto cohort ($n = 21$); *MTHFR 677TT* genotype, idiopathic infertility and folic acid supplementation use from the Montreal cohort ($n = 6$); and advanced aged from the Ottawa cohort ($n = 3$). Equal amounts of sperm DNA from these 30 participants were combined in order to make the pooled sperm DNA sample used. The WGBS-Pool library was constructed using the KAPA® High Throughput Library Preparation kit (Roche/KAPA® Biosystems). Briefly, $1\;\mu g$ of the sperm DNA was spiked with 0.1% (w/w) unmethylated $\lambda$ and pUC19 DNA (Promega). DNA was sonicated (S220 Focused-ultrasonicator, Covaris) and fragment sizes of $300–400\text{ \ bp}$ were controlled on a Bioanalyzer DNA 1000 LabChip® (Agilent). Following fragmentation, DNA-end repair of double-stranded DNA breaks, 3′-end adenylation, adaptor ligation, and clean-up steps were conducted according to KAPA® Biosystems' protocols. The sample was then bisulfite converted using the EpiTect® Fast DNA bisulfite kit (Qiagen) following the manufacturer's protocol. The resulting bisulfite DNA was quantified with OliGreen® (Life Technology) and amplified with 9--12 PCR cycles using the KAPA® HiFi HotStart $\text{Uracil} +$ DNA Polymerase kit (Roche/KAPA® Biosystems) according to suggested protocols. The final WGBS library was purified using Agencout® AMPure® Beads (Beckman Coulter), validated on Bioanalyzer High Sensitivity DNA LabChip® kits (Agilent) and quantified by PicoGreen® (ThermoFisher).

Targeted bisulfite sequencing was performed on the same 30-participant pooled sperm DNA sample used for WGBS (Capture-Pool) to compare the technique as well as on 45 individual samples ([Table 2](#t2){ref-type="table"}). These samples were chosen in order to examine the effect of *MTHFR* genotype alone from the Toronto cohort (*MTHFR 677CC* $n = 13$, *677TT* $n = 8$), and to examine the effect of folic acid supplementation and *MTHFR* genotype on a cohort of idiopathic infertile men from Montreal ($n = 6$ per genotype, before and after supplementation; i.e., 24 total samples). Following WGBS library preparations for all individual samples (as described above), the MCC-Seq protocol developed and optimized by Roche NimbleGen® was applied. Briefly, the SeqCap® Epi Enrichment System protocol (Roche NimbleGen®) was used to capture the regions of interest. Equal amounts of multiplexed libraries ($84\text{ \ ng}$ of each, 12 samples per capture) were combined to obtain $1\;\mu g$ of total input library, which was hybridized to the capture panel at 47°C for 72 h. Washing, recovery, and PCR amplification of the captured libraries, as well as final purification were conducted as recommended by the manufacturer. Bioanalyzer High Sensitivity DNA LabChip® kits (Agilent) were used to determine quality, concentration, and size distribution of the final captured libraries.

###### 

Demographics of samples assessed with the human sperm capture panel.

Table 2 has four columns. The first column lists the different determinants. The adjacent columns list values for Toronto, Montreal, pre-folic acid, and Montreal, post-folic acid values for cohort.

  Characteristic                                       Cohort                                    
  ---------------------------------------------------- -------------------- -------------------- --------------------
  Total number of participants ($n$)                   21                   12                   12
  Age                                                                                            
   $\text{Mean} \pm \text{SD}$                         $40.8 \pm 8.6\; y$   $39.3 \pm 8.2\; y$   $39.3 \pm 8.2\; y$
   Range                                               28--61 y             26--53 y             26--53 y
  Fertility status[^*a*^](#TF5){ref-type="table-fn"}   Fertile              Infertile            Infertile
  Sperm counts (million/mL)                                                                      
   $\text{Mean} \pm \text{SD}$                         $73.2 \pm 29.0$      $188.2 \pm 174.5$    $203.0 \pm 208.0$
   Range                                               38.0--140.0          27.5--536.5          46.9--674.8
  Percentage DFI (%)                                                                             
   $\text{Mean} \pm \text{SD}$                         $15.0 \pm 6.7$       $22.5 \pm 9.6$       $18.2 \pm 7.6$
   Range                                               6.1--30.9            7.7--39.42           7.64--27.6
  Smoking status ($n$)                                                                           
   Smokers                                             6                    0                    0
   Nonsmokers                                          15                   12                   12
  *MTHFR* genotype ($n$)                                                                         
   *MTHFR CC*                                          13                   6                    6
   *MTHFR TT*                                          8                    6                    6
  High-dose folic acid use \[$5\;{mg}/d$ ($n$)\]                                                 
   Yes                                                 0                    0                    12
   No                                                  21                   12                   0

Note: DFI, DNA fragmentation index; MTHFR, methylenetetrahydrofolate reductase; SD, standard deviation.

A fertile status was determined if participants were normospermic and presented to the clinic due to known female factor infertility (see "Methods" section).

The single WGBS-pool library was sequenced over four lanes using the Illumina® HiSeq2000 system, whereas the capture libraries were sequenced over eight lanes on the Illumina® HiSeq4000 system. All sequencing used $100\text{-\ bp}$ paired-end sequencing.

Sequencing Data Processing {#s2.5}
--------------------------

WGBS HiSeq reads were aligned to the bisulfite-converted reference genome hg19/GRCh37 using BWA (version 0.6.1) ([@c47]). Low-quality sequences (Phred score $< \, 30$) were trimmed from the 3′ end of paired reads. Following alignment, read-pairs not mapped at the expected distance based on the library insert size, as well as reads *a*) that were clonal/duplicates, *b*) with low mapping quality, *c*) mapping to both forward and reverse strands, and *d*) with $> 2\%$ mismatches were removed, as previously described ([@c37]). Individual CpG methylation calling was extracted using SAMtools (version 0.1.18) in mpileup mode.

Targeted MCC-Seq HiSeq reads were aligned using an in-house GenAP_pipe pipeline (<https://bitbucket.org/mugqic/genpipes>). Specifically, the MCC-Seq paired-end raw reads were first trimmed for quality ($\text{Phred\  }33 \geq 30$), length ($n \geq 50$), and Illumina® adapters using Trimmomatic (version 0.36) ([@c8]). The trimmed reads were then aligned, per sequencing lane, to the pre-indexed reference genome hg19/GRCh37 using Bismark (version 0.18.2) ([@c42]) with Bowtie 2 (version 2.3.1) ([@c43]) in pair-end mode and default parameters. Lane BAM files were merged and then de-duplicated using Picard (Broad Institute, version 2.9.0). Methylation calls were obtained using Bismark. BisSNP (version 0.82.2) ([@c49]) was run on the de-duplicated BAM files to call variants. For both WGBS and MCC-Seq data, CpGs that were found to be overlapping with SNPs (dbSNP 137), the Data Analysis Center (DAC) Blacklisted Regions or Duke Excluded Regions \[both generated by the Encyclopedia of DNA Elements (ENCODE) project\] were removed. CpG sites with less then $20 \times$ coverage were also discarded and genomic locations were annotated with HOMER, using default parameters. Sequencing data from WGBS and from MCC-Seq have been submitted to the European Genome-phenome Archive under the accession number EGAS00001003617.

Comparison with Other Human Sperm WGBS Data {#s2.6}
-------------------------------------------

Our WGBS-Pool data were compared with publically available data on human sperm from \[[@c52] (GSE3040; WGBS-Prev)\] where sperm DNA methylation data from two anonymous donors were pooled after sequencing. The processed data were downloaded (reference genome hg18) and were converted to the reference genome hg19 using the University of California, Santa Cruz (UCSC) Genome Browser tool Batch Coordinate Conversion (liftOver). Similar to our data, only sites with $\geq 20 \times$ coverage were used for analysis. For the comparison of common sites between the two data sets (WGBS-Pool vs. WGBS-Prev), the intersectBed feature of bedtools (version 2.27.0) was used to select overlapping sites.

Statistical Analyses {#s2.7}
--------------------

Generalized linear regression models (GLMs) were built using the methylation proportion inferred from the combination of methylated reads and unmethylated reads as a binomially distributed response variable to look for associations between DNA methylation and *a*) *MTHFR* genotype (e.g., *MTHFR 677CC* vs. *MTHFR 677TT*) or *b*) high-dose folic acid supplementation (e.g., before vs. after). We used the R function glm (R Development Core Team, version 3.2.1) and the binomial family to fit the model, and calculated *p*-values for variables of interest. We corrected the obtained *p*-values by generating false discovery proportion *q*-values using the R package *q*-values ([@c18]). We selected significant DMCs as *q* or nominal *p* $\leq 0.01$, with a minimum of methylation level difference of $\geq 10\%$. Specifically, for the comparison of *MTHFR* genotype (Toronto cohort; *677CC*: $n = 13$, *677TT*: $n = 8$), results were significant for *q* $\leq 0.01$ and a minimum methylation difference of 10%. For the effect of folic acid supplementation in the Montreal cohort ($n = 6$ per genotype, per time point), due to the relatively smaller sample size, significant results were reported for nominal *p* $\leq \, 0.01$ and a minimum methylation difference of 10%.

Graphs were made and statistical analyses performed using GraphPad Prism (version 6.01), and statistical significance was set at $p < 0.05$ for the analyses described below. Absolute values were compared by Fisher's exact test, when comparing smoking and alcohol consumption distributions among participants. *t*-Tests were performed to compare the age (unpaired), serum/red blood cell (RBC) folate levels (paired), and overall sperm DNA methylation levels (paired) between *MTHFR* genotypes or pre/post-folic acid supplementation. Unpaired *t*-test and analysis of variance (ANOVA) was used in examining DNA methylation variation. Enrichment of different publically available data sets was compared between the total number of sites analyzed through our human sperm capture panel and the different folate metabolism--related DMCs using $\chi^{2}$ test with Yates' correction.

Results {#s3}
=======

Deep WGBS on a Pooled Sperm DNA Sample {#s3.1}
--------------------------------------

We assembled an equimolar pool of sperm DNA from a subset of the participants recruited (30 men) varying in age, fertility status, *MTHFR* genotype, and exposures (folic acid supplements, smoking) ([Table 1](#t1){ref-type="table"}). By having such a wide cross section of men, we wished to assess the variation in human sperm DNA methylation caused by having a complex pool of sperm DNA. The men came from three Canadian cities: *a*) Toronto, a fertile cohort; *b*) Montreal, an idiopathic infertility cohort; and *c*) Ottawa, an aged cohort (see Excel Table S2). Imprinted gene methylation was assessed by bisulfite pyrosequencing to assess sample purity and rule out samples with somatic cell contamination (i.e., abnormal imprinted gene methylation affected equally across all imprinted gene loci); all samples were accepted because they each showed the expected methylation for sperm with $> 90\%$ methylation at the paternally methylated *H19* locus and $< 10\%$ methylation at the maternally methylated *MEST* locus ([Table 1](#t1){ref-type="table"}). A single WGBS library from the 30 men (WGBS-Pool) was prepared and sequenced to a depth of 1,672,735,160 raw reads, yielding an average CpG coverage of $23 \times$, which corresponded to an average genome-wide methylation of 74.1% (see Excel Table S3). Over 95% of CpG dinucleotides had sequence coverage ([Figure 1A](#f1){ref-type="fig"}).

![Whole genome bisulfite sequencing (WGBS) of human sperm DNA. (A) Examination of the genomic distribution of CpG sites found within the human genome (top) and from WGBS (bottom) of a pooled DNA sample (WGBS-Pool). (B) Analysis of highly covered ($> 20 \times$) sites from WGBS-Pool and that of WGBS-Prev examining their genomic distribution and their location within CpG islands, shores and shelves. (C) Genome browser view of DNA methylation tracks from WGBS-Pool and WGBS-Prev data sets. (D) Scatter plot of common CpGs sequenced at $> 20 \times$ between WGBS data sets. (E) Difference in DNA methylation of common CpG sites (WGBS-Pool minus WGBS-Prev, left). DNA methylation of sites congruent ($\pm 10\%$ methylation difference, shaded bars) and divergent ($> 10\%$ methylation difference, open bars) sites, right top and bottom, respectively. Human genome total CpG sites were derived from the human genome sequence and downloaded through the WashU EpiGenome Browser (<https://egg.wustl.edu/d/hg19/CpGsites.gz>). Note: chr, chromosome; CpG, 5′-cytosine-phosphate-guanine-3′; TSS, transcriptional start site; TTS, transcriptional termination site; UTR, untranslated region; WGBS-pool, WGBS library pool; CCDS, consensus coding sequence; WGBS-Prev, publically available data on human sperm from Molaro et al. ([@c52]).](ehp-127-087002-g0001){#f1}

Comparing our WGBS-Pool with a previous WGBS data set looking at human sperm DNA methylation from two individual participants (WGBS-Prev; [@c52]), we covered 1.7-times more CpG sites at $\geq 20 \times$ coverage ([Figure 1B,C](#f1){ref-type="fig"}). The average methylation of the highly covered sites was found to be 80.5% and 69.4% for our WGBS-Pool and WGBS-Prev, respectively ([Figure 1B](#f1){ref-type="fig"}, table). This difference in methylation may be explained by the fact that a greater proportion of highly covered sites from the WGBS-Prev was found within promoter--transcriptional start site (TSS) regions as well as within CpG islands ([Figure 1B](#f1){ref-type="fig"}, bottom); these features generally show hypomethylation and would therefore reduce the overall DNA methylation. Although the WGBS-Pool data sequenced more CpG sites at high coverage, comparing the methylation of common sites with the published data demonstrated similar DNA methylation levels ([Figure 1C,D](#f1){ref-type="fig"}); a total of 5,395,997 common CpGs were sequenced and showed a strong correlation ($r = 0.93$). When examining the difference in methylation of the common/overlapping sites between the two data sets, a large majority of the CpGs (5,022,176 sites; 93.1%) demonstrated congruent/similar ($< 10\%$ difference) methylation ([Figure 1E](#f1){ref-type="fig"}, shaded bars) and displayed mainly low ($\leq 20\%$) or high ($\geq 80\%$) levels of methylation. Conversely, divergent CpGs, where a $> 10\%$ methylation difference between data sets was observed (373,821 sites; open bars), demonstrated mainly intermediate levels of methylation, between 20% and 80%.

Because our WGBS-Pool was generated from DNA from 30 individuals, creating a complex pool, we hypothesized that sites of intermediate methylation would contain sites of dynamic methylation due to variability in sperm methylation states (intra- and inter-individual). Interestingly, in a recent study using blood and adipose tissue, it was demonstrated that environmental differentially methylated regions (DMRs) possess intermediate methylation, outside of the hypomethylated promoter areas ([@c11]). Techniques, such as RRBS, interrogate high-CpG density sequences, which normally show relatively stable hypomethylation ([Figure 2A](#f2){ref-type="fig"}, left panel; data from Aarabi et al. ([@c2]). In line with this, we found from our WGBS-Pool data ([Figure 2A](#f2){ref-type="fig"}, right) that a significant proportion of CpGs possessing 0--20% methylation mapped within promoter-TSS regions (defined as $- 1\text{ \ kb}$ to $+ 100\text{ \ bp}$ from TSS), which tend to harness low variation ([Figure 2B](#f2){ref-type="fig"}, Low). More specifically, 74.6% of all CpGs found within promoter-TSS regions within the genome possessed $< 20\%$ methylation. Our data also demonstrated that the large majority of sequenced CpGs possessed methylation between 80% and 100% ([Figure 2A](#f2){ref-type="fig"}, right panel). Intermediate-level methylation (i.e., 20--80%) was observed in the WGBS-Pool for 2.01 million CpGs, as compared with 0.26 and 1.75 million sites from RRBS and WGBS-Prev, respectively ([Figure 2C](#f2){ref-type="fig"}); these intermediate sites were concentrated to intergenic CpGs as well as sites in intronic regions, and both areas contained distal sequences that can regulate gene activity ([Figure 2B](#f2){ref-type="fig"}, Intermediate).

![Distribution of sperm DNA methylation from our WGBS-Pooled sample. (A) Percentage of CpGs with specific DNA methylation ranges sequenced from RRBS (left) the WGBS-Pool ($> 20 \times$, right). (B) Genomic distribution of CpG sites with low (0--20%), intermediate (20--80%), and high (80--100%) DNA methylation from WGBS-Pool data. (C) Number of CpG sites demonstrating intermediate levels of DNA methylation interrogated by RRBS, WGBS-Prev, and WGBS-Pool. WGBS-Prev data is from [@c52]. RRBS data is from [@c2]. Note: CpG, 5′-cytosine-phosphate-guanine-3′; RRBS, reduced representation bisulfite sequencing; TSS, transcriptional start site; TTS, transcriptional termination site; UTR, untranslated region; WGBS, whole genome bisulfite sequencing; WGBS-pool, WGBS library pool; WGBS-Prev, publically available data on human sperm from Molaro et al. ([@c52]).](ehp-127-087002-g0002){#f2}

Sperm Methylation Capture Design for MCC-Sequencing {#s3.2}
---------------------------------------------------

We designed a capture panel targeting regions of intermediate methylation in human sperm as a cost-efficient alternative to shotgun WGBS. Specifically, in order to target regions of intermediate levels of methylation, sliding windows of $150\text{ \ bp}$ bins, containing a minimum of two consecutive CpGs, were constructed using our WGBS-Pool data. The methylation levels of each bin were calculated, sorted and binned regions with a minimum absolute difference from the 50% methylation level were retained (250,000 bins above and below); overlapping bins were further merged. In addition, to allow comparisons with human sperm DNA methylation profiles generated by us and others using Illumina® arrays ([@c5]; [@c13]; [@c35], [@c36]; [@c41]), the complete set of CpGs from the $850K$ array ($n \sim 850,000$) was added. Upstream and downstream $50\text{-bp}$ flanking regions were added to each individual probe location and were then added to those determined through our WGBS data, with overlapping regions merged.

Our design for the human sperm methyl capture yielded $107.14\text{ \ Mb}$ of sequence targetable by Roche NimbleGen® for synthesis of a custom SeqCap® Epi probe panel, containing 830,188 regions capturing 3,179,096 CpG sites. These targeted sites were found mainly in *a*) intergenic (34%), intronic (33%), and promoter-TSS (19%); *b*) CpG island; and *c*) nonrepetitive regions and were dispersed throughout the genome ([Figure 3A](#f3){ref-type="fig"}; see also Figure S1A). Of the $\sim 3.18\text{ \ million}$ CpG sites on the human sperm capture panel, 937,141 sites represented those derived from our WGBS-Pool data possessing regions of intermediate methylation (i.e. intermediate methylation captured CpGs); the remainder represented $850K$-derived sites ([Figure 3B](#f3){ref-type="fig"}).

![Creation and validation of the human sperm capture panel. (A) Sites captured by the human sperm capture panel analyzing their distribution by genomic regions (left); within CpG island, shores, and shelves (middle); and within repetitive elements (right). (B) Summary of different techniques and their features (top, table). Comparison of the number of sites analyzed that are intermediate methylation captured CpGs (labeled "Intermediate" methylation CpGs), 850K dereived CpGs and other EPIC-related CpGs from different assays. (C) Capture sequencing information of the 30-participant pooled sperm DNA sample (Capture-Pool). (D) Scatter plot analysis of DNA methylation of common sites found by sequencing the pooled DNA samples using the targeted human sperm capture panel (Capture-Pool) and by WGBS (WGBS-Pool). (E) Difference in methylation (Capture-Pool minus WGBS-Pool) of the common CpG sites. Note: CpG, 5′-cytosine-phosphate-guanine-3′; diff, difference; LINE, long interspersed nuclear elements; LTR, long terminal repeats; SINE, short interspersed nuclear elements; TSS, transcriptional start site; TTS, transcriptional termination site; UTR, untranslated region; WGBS-pool, WGBS library pool.](ehp-127-087002-g0003){#f3}

Comparing the human sperm methyl capture with other techniques available, we noted that the commercially available TruSeq® Methyl Capture EPIC (EPIC capture) from Illumina® targets a similar DNA sequence footprint and total number of CpG sites, although fewer regions ([Figure 3B](#f3){ref-type="fig"}). The largest differences are observed for intermediate methylation captured CpG sites captured, and although these constitute approximately one-third of our human sperm capture panel, they represent a small proportion of the sites analyzed with the $850K$ array or the EPIC capture (5.2% and 3.8% of sites, respectively) ([Figure 3B](#f3){ref-type="fig"}, bottom and Figure S1B). Notably, the intermediate methylation captured CpGs sites are found mainly in intergenic and outside of CpG-dense areas of the genome, whereas CpG sites covered by the other techniques include a greater proportion of promoter-TSS regions and CpG islands (see Figure S1C). EPIC-related CpGs not sequenced by our human sperm methyl capture panel, were mainly found in repetitive elements and immediately flanking CpG-dense areas in the EPIC design (see Figure S2). Finally, as compared with microarray technologies, the capture sequencing allowed for the measurement of genetic in parallel with epigenetic variation (see below and the "Methods" section).

Variation in DNA Methylation in Intermediate Methylation Captured CpG Sites {#s3.3}
---------------------------------------------------------------------------

We hypothesized that the intermediate methylation captured CpGs sites on our human sperm capture panel, derived from our WGBS-Pool data, would represent sites with dynamic methylation. In other words, these sites would demonstrate higher variability in methylation compared with other sites sequenced. To test this, the panel was used to capture and sequence 45 individual human sperm samples (21 individuals from Toronto and 12 individuals with two time points from Montreal, discussed further below). Examining only sites targeted and sequenced with $\geq 20 \times$ coverage in at least 30 of the 45 participants, we calculated the standard deviation of each CpG. As shown in Figure S3, the intermediate methylation captured CpG sites ($n = 571,584$) had significantly higher average variation ($\sim 5\text{-fold}$) compared with $850K$-derived sites found on our capture panel ($n = 1,104,764$). Because the numbers of sites differed between the intermediate methylation captured and $850K$-derived CpGs, we randomly chose subsets of the $850K$-derived CpGs in order to obtain similar numbers (permutated five times); the results were similar, with intermediate methylation captured CpGs demonstrating significantly greater variation. With these results, hereafter, we denote intermediate methylation captured CpGs as dynamic sperm CpG sites.

Validation with Targeted Sequencing of Pooled Sperm DNA {#s3.4}
-------------------------------------------------------

In order to validate the use of the human sperm capture panel, the same pooled sperm DNA used for the WGBS-Pool was sequenced following targeted capture (Capture-Pool). We observed a minimum of $1 \times$ coverage at a total of 11.1 million CpGs (average $8.3 \times$) ([Figure 3C](#f3){ref-type="fig"}). A large proportion of these CpGs sequenced were found in regions not intentionally targeted by our panel due to nonspecific/off-target capture of other genomic sequences; these sites are covered at low depth and demonstrated an average coverage of $4.2 \times$ (see Figure S4A). By contrast, we saw enrichment of our targeted sites where 3.13 million CpGs ($> 98\%$ of targets) were sequenced, demonstrating an intermediate methylation (46.7%) at an elevated average coverage of $18.5 \times$ ([Figure 3C](#f3){ref-type="fig"}; see also Figure S4B).

Comparing common sites sequenced from the WGBS-Pool and Capture-Pool data, 767,417 CpG sites were sequenced at a minimum $20 \times$ coverage using both techniques and showed a correlation of $r = 0.97$ ([Figure 3D](#f3){ref-type="fig"}). Examining the difference in methylation detected between the two sequencing methods, greater than 75% of common sites demonstrated $< 10\%$ methylation difference between the techniques; at a level of 20% difference in methylation, 95% of common sites were included ([Figure 3E](#f3){ref-type="fig"}). In addition, the sequencing coverage affected the correlation particularly at dynamic sperm CpG sites (see Figure S4C). When examining sites specifically targeted by our human sperm capture panel, from our deep sequencing of the WGBS-Pool, we obtained approximately $22.7 \times$ coverage for these sites from over 1.67 billion reads (see Excel Table S3). In comparison with our Capture-Pool targeted sequencing, with only a little over 46.5 million reads, we obtained a similar coverage of targeted sites ($18.6 \times$). Thus, targeted CpGs were equally covered at only 3.4% raw data depth of the shotgun WGBS, improving cost-efficiency for population studies.

MCC-Sequencing in Sperm from Individual Men {#s3.5}
-------------------------------------------

We next utilized the human sperm methyl capture panel to assess the effect of two different, yet related, perturbations of folate metabolism: *a*) samples from the Toronto fertile cohort, to examine the effect of *MTHFR* genotype; and *b*) participants from the Montreal infertile cohort, to examine the interaction of *MTHFR* genotype and high-dose folic acid supplementation (before vs. after; [Table 2](#t2){ref-type="table"}). Specifically, a different subset of sperm from 21 men from the CReATE fertility clinic in Toronto was used. Because they presented at the clinic due to known female factor infertility, they were considered to be fertile. As well, 12 healthy normospermic participants were used from the Montreal cohort, where semen samples were collected before and after a folic acid supplementation (i.e., a total of 24 samples); this subset of participants was previously analyzed using RRBS ([@c2]). These men presented with idiopathic infertility given that female factor infertility was excluded. Although a significant difference in sperm counts was observed between the Toronto and Montreal cohorts ([Table 2](#t2){ref-type="table"}), all men analyzed with the human sperm capture (45 men in total) were considered normospermic because they met the criteria according to WHO guidelines ($> 15 \times 10^{6}\text{sperm}/{mL}$; [@c19]). This difference in sperm counts may be due to methodology or counting biases used at the different sites.

Principal component analysis (PCA) was performed for all the individual libraries based on genotyping data extracted from the methylome sequencing (see "Methods" section; see also Figure S4D). Given that $< 10\%$ of the variance can be explained by the first two principal components ($\text{PC}1 = 4.75\%$ and $\text{PC}2 = 4.05\%$), the genetic ancestry of the participants is comparable and would not be considered a confounder. Similar to the Capture-Pool library preparation, on average approximately $12.2 \pm 0.58\text{ \ million}$ CpGs were sequenced at a minimum $1 \times$ coverage, whereas targeted regions showed an enrichment of highly covered CpGs (average $3.14 \pm 0.0038\text{ \ million}$ CpGs at $27.6 \pm 3.72$-fold coverage; see Figure S4E and Excel Table S3).

Imprinted Gene DNA Methylation Patterns from Targeted Sequencing {#s3.6}
----------------------------------------------------------------

We examined in greater detail the sperm DNA methylation patterns at several imprinted genes because abnormal sperm DNA methylation patterns at imprinted loci have previously been observed in men suffering from infertility ([@c40]; [@c46]; [@c57]). [Figure 4](#f4){ref-type="fig"} depicts regions of two imprinted genes, *H19* and *MEST*, and shows the methylation of highly covered CpG sites from an individual CC and TT patient (CC and TT genotype tracks, respectively). On inspection of the imprinted loci and their ICRs, we observed that the $850K$ array interrogated only a subset of the CpG sites found within the regions. This can be seen particularly at the paternally methylated *H19* ICR ([Figure 4A](#f4){ref-type="fig"}), where only two $850K$-array probes are located ($850K$ track), compared with the human sperm capture, where 17 sites are targeted (Capture CpG track). As with many maternally methylated ICRs, the *MEST* ICR is found within a CpG island and is well covered with the different assays ([Figure 4B](#f4){ref-type="fig"}).

![Examination of imprinted gene methylation from human sperm capture sequencing data. UCSC Genome Browser view of the imprinting control centers (ICRs, green regions) of (A) the paternally methylated gene *H19*, and (B) the maternally methylated gene *MEST*. Custom tracks indicate CpG sites (green), CpGs analyzed by Infinium MethylationEPIC array (black), TruSeq® Methyl Capture EPIC (blue), our human sperm Capture (gold), and Dynamic CpG sites (light green). Tracks for representative capture sequencing data (all sequenced sites with $> 20 \times$ coverage are shown) for a CC individual (red) and a TT individual (dark green) are shown. As compared with the gold tracks, which show only on-target CpGs (of a total of 3.13 million; see [Figure 3C](#f3){ref-type="fig"}), more CpG sites are marked in the CC and TT tracks as sites sequenced at $> 20 \times$ coverage are shown (of a total of 11.1 million as shown in [Figure 3C](#f3){ref-type="fig"}). Note: chr, chromosome; CpG, 5′-cytosine-phosphate-guanine-3′; DMR, differentially methylated region; ICR, imprinting control region; UCSC, University of California, Santa Cruz; CDDS, consensus coding sequence.](ehp-127-087002-g0004){#f4}

Earlier bisulfite pyrosequencing of these imprinted loci examined only a few sites within the ICR of two imprinted genes (5 and 10 CpG sites for *H19* and *MEST*, respectively). The high-density data (17 and 126 sites for *H19* and *MEST*, respectively) obtained using the human sperm capture panel on the 45 individual samples demonstrated no significant *MTHFR* genotype- or folic acid-dependent variation in these and other ICRs (see Figure S5). Although no differences were found in ICR methylation, a DMR could be observed just upstream of the *H19* promoter when comparing *MTHFR* genotypes of two individual subjects ([Figure 4A](#f4){ref-type="fig"}, shaded area).

Impact of Lifelong MTHFR Deficiency on Sperm DNA Methylation {#s3.7}
------------------------------------------------------------

The first phenotypic correlations we carried out using the human sperm capture panel interrogated the effect of a common human functional polymorphism in *MTHFR* on sperm DNA methylation given that we have previously demonstrated that functional *Mthfr* variation in mice is a global sperm methylation modifier ([@c1]). In mice, MTHFR is expressed at higher levels in the testis than any other tissue ([@c15]). Because *MTHFR 677TT* individuals have a genetic deficiency that results in a thermolabile form of the enzyme with $\sim 50\%$ of residual activity ([@c38]), they have the equivalent of a lifelong MTHFR deficiency; such deficiency could impact DNA methylation patterning in the fetal or postnatal testis. Here, sperm from 13 *MTHFR 677CC* and 8 *677TT* fertile men from Toronto were analyzed (mean genome coverage of $29.1 \times$ and $29.2 \times$, respectively). Both groups were similarly distributed based on age ($41.8 \pm 10.0\; y$ and $39.1 \pm 6.0\; y$), smoking (4 of 13 and 2 of 8 participants) and alcohol consumption (3 of 13 and 2 of 8 participants, for *677CC* and *TT*, respectively). Figure S6A shows Q-Q and Manhattan plots of association *p*-values for tested sites. From these, a total of 13,428 DMCs were found to be significantly altered due to *MTHFR* genotype, at a false discovery rate of $q \leq 0.01$ and a minimum of 10% difference in methylation, and were found mainly in intergenic and intronic regions of the genome ([Figure 5A](#f5){ref-type="fig"}). A greater number of sites were found to have increased methylation in *MTHFR 677TT* compared with *MTHFR 677CC* men (8,756 hyper- vs. 4,672 hypomethylated DMCs; [Figure 5B,C](#f5){ref-type="fig"}). Interestingly, a vast majority (86.7%) of the DMCs discovered were those shown to be dynamic sperm CpG sites, uniquely targeted in our assay. DMCs were commonly annotated to the same gene/region within the genome and predominantly found clustered together (see Excel Table S4). Examples include several intergenic regions, the promoter and first exon/intron of the noncoding RNA *LOC100130872*, and within the introns of *SAMD11*, transcription elongation factor B polypeptide 3C-like (*TCEB3CL*), and disks large-associated protein (*DLGAP2*). The differential methylation of several DMCs was validated using bisulfite pyrosequencing: An intron of *SAMD11* (5 CpGs; [Figure 5D](#f5){ref-type="fig"}) and an intergenic region (4 CpGs; [Figure 5E](#f5){ref-type="fig"}) demonstrated excellent concordance in DNA methylation between bisulfite pyrosequencing and human sperm capture panel results. Inter-individual variability between participants within each group was observed and also validated (see Figure S7 and Excel Table S5).

![Effect of MTHFR genotype, in Toronto cohort men, on sperm DNA methylation. Total number of DMCs between human *MTHFR 677CC* ($n = 13$) and *677TT* ($n = 8$) genotypes with their (A) genomic region distribution, (B) demonstrating mainly hypermethylation and changes in dynamic sperm CpG sites, and (C) differences in methylation between genotypes. Pyrosequencing® validation of several DMCs found within (D) an intron of *SAMD11* and (E) an intergenic region. $\text{Mean} \pm \text{standard\ error}$. Note: chr, chromosome; CpG, 5′-cytosine-phosphate-guanine-3′; DMCs, differentially methylated cytosines; hyper, hypermethylated; hypo, hypomethylated; *MTHFR*, methylenetetrahydrofolate reductase; *SAMD11*, sterile alpha motif domain containing 11; TSS, transcriptional start site; TTS, transcriptional termination site; UTR, untranslated region.](ehp-127-087002-g0005){#f5}

The *MTHFR 677TT* genotype-associated differences in methylation are reminiscent of those we reported in mice heterozygous for a targeted mutation in *Mthfr*, a model for MTHFR deficiency similar to that found in *MTHFR 677TT* men ([@c1]). Our previous sperm DNA methylation data generated with RRBS were reanalyzed to generate individual CpG data. Similar to the present results, the majority of the DMCs were found in intergenic and intronic regions (see Figure S6B) and revealed hypermethylation in $Mthfr^{+ / -}$ mice compared with their wild-type littermates (Figure S6C,D); 8,549 DMCs were found to have an increased level of methylation in $Mthfr^{+ / -}$ mice, whereas 407 sites showed decreased levels.

Impact of Short-Term Folic Acid Exposure on Sperm DNA Methylation {#s3.8}
-----------------------------------------------------------------

We selected a subset of men ($n = 6$ *MTHFR 677CC* and $n = 6$ *MTHFR 677TT*) who had also been examined earlier by us using RRBS ([@c2]), and we used the human sperm methyl capture panel to analyze the effect of 6 months of treatment with high-dose folic acid supplements ($5\;{mg}/d$) on sperm DNA methylation. Six months of folic acid supplement treatment covers two rounds of spermatogenesis and can be considered a short-term perturbation of folate metabolism when compared with the long-term (lifelong) effect of *MTHFR* genotype described above. All men in this cohort were nonsmokers, and were equally distributed based on age ($36.5 \pm 6.5\; y$ and $42.4 \pm 8.0\; y$ for *677CC* and *TT*, respectively); alcohol consumption was not recorded for this cohort. Serum and RBC folate levels were previously measured ([@c2]), and reanalysis of the subset of men used in our present study demonstrated similar results, where no differences between *MTHFR* genotype were observed; however, elevated serum (see Figure S8A) and RBC (see Figure S8B) folate levels were observed following supplementation. We compared group effects of supplementation on DNA methylation in both *MTHFR* genotypes separately (see Figure S9A,B). Because of the small number of participants with each genotype, sites were nominated to be differentially methylated with $p \leq 0.01$ and a minimum of 10% difference in methylation. Similar to our previous results, the overall sperm DNA methylation from each *MTHFR* genotype was not affected following high-dose folic acid supplementation (*677CC*: $46.24 \pm 0.30\%$ and $46.36 \pm 0.54\%$; *677TT*: $46.12 \pm 1.54\%$ and $45.84 \pm 1.23\%$, baseline and following supplementation, respectively). However, supplementation resulted in 4,039 and 7,301 DMCs in the *MTHFR 677CC* and *677TT* groups, respectively, and were distributed similarly in terms of genomic regions ([Figure 6A](#f6){ref-type="fig"}; see also Excel Tables S6 and S7). The *677CC* genotype was associated with a slight tendency for increased DNA methylation (2,343 hyper- and 1,696 hypomethylated DMCs; [Figure 6B](#f6){ref-type="fig"}). Similar to our reported RRBS findings, men with the *MTHFR 677TT* genotype showed a significantly higher proportion of hypomethylated sites in sperm ($p \leq 0.0001$, $\chi^{2}$ test with Yates' correction); 4,765 sites demonstrated loss, whereas 2,535 sites showed increases in methylation. Similar to genotype effects seen in the Toronto samples, approximately 80% of DMCs for both genotypes were discovered to be dynamic sperm sites. In addition, paralleling *MTHFR* genotype effects, altered methylation was found close to or within *SAMD11* and *DLGAP2* following folic acid supplementation in both *677CC* and *677TT* subjects

![Effect of folic acid supplementation on the human sperm DNA methylome. (A) Genomic distribution of DMCs found in *MTHFR 677CC* (top, $n = 6$) and *677TT* (bottom, $n = 6$) following 6-month folic acid supplementation. (B) DMCs breakdown by hypo- and hypermethylation as well as dynamic sperm CpG sites. Gene Ontology (GO) analysis for enrichment of biological processes in DMCs found within genic regions from subjects of (C) *677CC* and (D) *677TT* genotypes. Note: CpG, 5′-cytosine-phosphate-guanine-3′; dev, development; diff, differentiation; DMCs, differentially methylated cytosines; *MTHFR*, methylenetetrahydrofolate reductase; TSS, transcriptional start site; TTS, transcriptional termination site; UTR, untranslated region.](ehp-127-087002-g0006){#f6}

To ensure low sampling bias (comparing our earlier larger RRBS study to the current proof-of-principle capture study), we restricted the comparison of RRBS and human sperm capture panel results to the same 12 *MTHFR 677CC* and *677TT* individuals included in both studies. We observed convergence of measured effects by the independent methods: *677TT* men being more affected than *677CC* men and also having a greater loss of sperm DNA methylation following supplementation (see Figure S9C). Gene ontology (GO) analysis, using DMCs found within genes, identified an enrichment of biological processes related to nervous system development and neuron differentiation for *MTHFR 677CC* and *677TT* genotypes in both the human sperm capture panel data ([Figures 6C,D](#f6){ref-type="fig"}, respectively) and the reanalysis of RRBS data (see Figure S9D,E, respectively).

Response to Long- vs. Short-Term Perturbations in Folate Metabolism {#s3.9}
-------------------------------------------------------------------

As previously mentioned, many sites demonstrating differential methylation were annotated within the same gene/region. We therefore merged neighboring DMCs found within close proximity (within $50\text{ \ bp}$) to determine whether there were regions of differential methylation. When examining the effect of the *MTHFR* genotype, 40% of DMCs (5,384 sites) remained as isolated CpG sites ([Figure 7A](#f7){ref-type="fig"}, left). Combining DMCs within $50\text{ \ bp}$ resulted in 2,450 merged regions, with the largest found to be $417\text{ \ bp}$ ([Figure 7A](#f7){ref-type="fig"}, right). In contrast, the use of folic acid supplementation for both *MTHFR 677CC* and *677TT* groups showed that many of the altered DMCs remained as individual CpG sites (92% and 84%, respectively; [Figure 7B,C](#f7){ref-type="fig"}, respectively); only 188 (maximum $69\text{ \ bp}$) and 495 (maximum $121\text{ \ bp}$) merged regions were discovered, respectively. The largest 10 merged regions from each comparison are listed in Excel Table S8. Thus, folic acid supplementation resulted in fewer and smaller merged regions.

![Regions of differential methylation following folate metabolism perturbations. (A) Comparisons of *MTHFR 677CC* vs. *677TT* genotypes and effect of folic acid supplementation in (B) *677CC* or (C) *677TT* participants were examined: left panels---total DMCs, isolated single CpG sites, and merged regions obtained after neighboring DMCs found within $50\text{ \ bp}$ were merged; right panels---size distribution of merged regions. Note: CpG, 5′-cytosine-phosphate-guanine-3′; DMCs, differentially methylated cytosines; *MTHFR*, methylenetetrahydrofolate reductase.](ehp-127-087002-g0007){#f7}

The stark contrast between the effects of *MTHFR* genotype effect vs. high-dose folic acid supplementation can be observed in [Figure 8](#f8){ref-type="fig"}. *MTHFR 677TT* subjects showed higher levels of methylation compared with *MTHFR 677CC* subjects within the seventh intron of *DLGAP2* ([Figure 8A](#f8){ref-type="fig"}). Here, six regions (ranging from a single CpG site to $109\text{ \ bp}$ in size) were found encompassing 25 DMCs showing 15--20% hypermethylation due to the *MTHFR* $677C > T$ polymorphism. Interestingly, all the altered sites were found to be dynamic sperm CpGs. Examining the effect of folic acid supplementation in *MTHFR 677TT* subjects, the largest DMR ($121\text{ \ bp}$ in size) was found within the first intron of epidermal growth factor receptor (*EGFR*) and contained four dynamic sperm CpG sites demonstrating decreased methylation (12--20% loss) after supplementation.

![Observed differential methylation due to *MTHFR* genotype and following folic acid supplementation. Examples showing regions of differential methylation seen between (A) men with *MTHFR 677CC* compared with *677TT* genotype or (B) following high-dose folic acid supplementation in *677TT* subjects. Note: chr, chromosome; *MTHFR*, methylenetetrahydrofolate reductase; UCSC, University of California, Santa Cruz; CCDS, consensus coding sequence.](ehp-127-087002-g0008){#f8}

Functional Correlates of Folate Metabolism--Related Differential DNA Methylation {#s3.10}
--------------------------------------------------------------------------------

Finally, it is possible that the folate metabolism--associated altered sperm DNA methylation relates to functional or sensitive areas in the genome. We therefore determined whether the DMCs or the merged regions we identified overlapped with putative functional regions from published studies. Although some overlap was found with histone modifications, evolutionarily constrained elements, and conserved sperm DNA methylation patterns, no enrichment was seen above background of the human sperm capture panel (see Figure S10A--F).

We next examined whether sites or regions would be similarly affected following different perturbations or exposures. Within our present results, few DMCs/regions overlapped when comparing effects of *MTHFR* genotype vs. those of folic acid supplementation. Interestingly, few altered DMCs were in common between *MTHFR 677CC* and *677TT* subjects following folic acid supplementation (see Figure S10H). WGBS was recently used to assess the effect of serum dioxin concentrations on the sperm DNA methylome. Again, few regions intersected with the DMCs found in our current study (see Figure S10G). Although there appears to be no specific susceptible regions in human sperm DNA methylation, exposure-specific signatures may be present.

Discussion {#s4}
==========

We applied WGBS on a population pooled sperm DNA sample to develop a targeted capture panel for the analysis of variable human sperm DNA methylation. This human sperm methyl capture panel not only targets the commonly assessed gene promoter/CpG island regions but also captures novel dynamic sperm DNA methylation sites at innocuous putative distal regulatory elements. These dynamic sperm sites represented the majority of CpGs differing in methylation levels between individuals with altered one-carbon metabolism (MTHFR deficiency) and those given high-dose folic acid supplements.

Several targeted capture panels have been designed including those that examine the DNA methylome across different cells and tissues ([@c69]) and those that are more tissue-specific, for instance, an adipose tissue--targeted panel ([@c4]). The sperm epigenome, with its low retention of histones ($< 15\%$ in humans) ([@c32], [@c31]) and specialized DNA methylome ([@c68]), differs greatly from that of other cell types, indicating that development of a customized sperm panel is warranted. The approach we chose to use, in order to discover variable regions in the sperm DNA methylome, utilized a pool of sperm DNA from a diverse group of men. Although we were able to cover nearly twice as many CpG sites at $\geq 20 \times$ coverage, our new human sperm WGBS data set compared well with the published WGBS data set from two normospermic men ([@c52]), especially for sites with methylation levels $< 20\%$ or $> 80\%$. In contrast, CpG sites where DNA methylation differed by $> 10\%$ between the two WGBS data sets were mostly found to possess intermediate levels of methylation (20--80%). In addition, with our WGBS-Pool data set we were able to identify about 260,000 more novel sites of intermediate methylation, likely due to inter-individual variation in the pooled discovery cohort, compared with RRBS ([@c2]) or other WGBS data on single/two pooled samples ([@c52]). Our results underscore the importance of assessing population as well as tissue lineage-dictated differences in epigenetic landscapes.

Our customized sperm capture design incorporated the regions of intermediate methylation identified by WGBS, which were found to be more variable than other CpG sites targeted and were denoted as dynamic sperm CpGs. These sites represented roughly a third of the $\sim 3.18\text{ \ million}$ targeted CpGs; in contrast, $< 5\%$ of dynamic sperm CpGs are detected by the $850K$ array or EPIC Capture. Using the WGBS-pool sample to test our capture panel allowed us to confirm that the panel we designed was able to accurately, and at high coverage, capture close to 100% ($\sim 3.13\text{ \ million}$) of the targeted CpGs. Moving on to individual samples, the sperm capture results recapitulated DNA methylation levels of genes, such as imprinted genes, that have been well studied in sperm.

Folate metabolism is important for the synthesis of nucleic acid precursors and amino acids and the production of *S*-adenosylmethionine (SAM), the universal methyl donor ([@c6]). It is therefore not surprising that polymorphisms in *MTHFR*, a crucial enzyme within this pathway, would lead to altered DNA methylation. With our capture panel, participants homozygous for the $677C > T$ polymorphism demonstrated altered sperm DNA methylation, with a greater tendency for hypermethylation. This is in line with our previous animal study demonstrating increased sperm DNA methylation in mice haplo-insufficient for the *Mthfr* gene and considered a model for *MTHFR 677TT* individuals ([@c1]). A large proportion of the observed changes were found to be dynamic sperm sites and would not have been detected with other currently available techniques. Furthermore, many of the sites altered due to genotype were increases in sperm DNA methylation. Altered methyl pools and SAM due the *MTHFR* *677TT* variant may affect other epigenetic marks, such as H3K4 methylation. Particularly, H3K4me3 is anticorrelated with DNA methylation ([@c55]); therefore, decreases in this histone modification may have resulted in increased levels of DNA methylation at specific sites.

The human sperm methyl capture panel was also used to reevaluate the effect of high-dose folic acid supplementation on a cohort of infertile participants ([@c2]). Use of folic acid resulted in altered DNA methylation patterns in sperm, dependent on the participants' *MTHFR* genotype. A greater tendency for hypermethylation was observed in *MTHFR 677CC* subjects, whereas significant hypomethylation was seen in those homozygous for the *T* allele. Results here, along with similar results from our previous human and animal model studies, provide further support for our proposal that high circulating and testicular folate levels down-regulate MTHFR, decreasing methyl group availability and leading to loss of DNA methylation ([@c1]). Here, we again discovered that the vast majority of sites with altered methylation, after short-term use of high-dose folic acid supplements, were dynamic sperm CpGs.

Along with infertility, the *MTHFR* $677C > T$ polymorphism has been associated with cancer, vascular, neurological, and psychiatric diseases ([@c48]). *MTHFR 677TT* subjects were found to have significantly increased methylation at several CpG sites/regions within *SAMD11* and *DLGAP2*. *SAMD11* has been found to be a strong candidate gene for autism spectrum disorders through a whole exome sequencing study ([@c14]). Similarly, in an animal model of post-traumatic stress disorder caused by an environmental stress, specific hypermethylation within *Dlgap2* and decreased expression were associated with the effects of a traumatic environmental stressor ([@c16]). High-dose folic acid supplementation also resulted in altered methylation around these two genes, although only at a few CpG sites. Interestingly however, GO analysis from both *MTHFR 677CC* and *677TT* individuals showed enrichment in biological processes involving neurogenesis following supplementation.

In addition to enrichment for GO analysis, we examined other functional aspects of the altered sites found in our study. It has been reported, so far, that histone retention in sperm is found predominantly at promoters, which are hypomethylated ([@c10]; [@c32], [@c31]); thus, it would not be expected to show great enrichment in our data. Along similar lines, a large proportion of constrained elements, often indicating regions of functional importance, are found mainly in known exons, as well as 5′ and 3′ untranslated regions (UTRs) ([@c20]), regions showing little alterations in sperm DNA methylation following perturbations. Finally, it has been reported that an evolutionary expansion of hypomethylated regions in the genome was found ([@c58]); the majority of DMCs we discovered were within dynamic sperm sites, possessing intermediate levels of methylation; therefore, no enrichment was observed as well.

A differential response was observed between our different perturbations to folate metabolism. We discovered that men homozygous for the *MTHFR* $677C > T$ polymorphism demonstrated a larger number of DMCs when compared with *MTHFR 677CC* individuals; altered sites detected were found within close proximity, resulting in regions of differential methylation. An altered sperm DNA methylome due to *MTHFR* genotype is the result of a persistent/lifelong perturbation given that the polymorphism was present since fertilization. The highest enzyme activity of MTHFR in mice was observed in the testes ([@c15]), and studies from our lab have demonstrated that protein expression was detected in pre- and postnatal mouse germ cells ([@c27]). Specifically, in mice, the expression of MTHFR was detected at the highest levels during the major time of DNA methylation acquisition (embryonic day 15--18; [@c27]). Therefore, the observed results may be due to a lifetime altered methyl pool availability and SAM, particularly during *in utero* development, causing disruptions during male germ cell DNA methylation pattern establishment over larger regions in the genome.

Although genotypic differences of *MTHFR* examined lifelong perturbations, the effects seen in our supplementation study reflect short-term/acute perturbations. Subjects within this group were given high-dose folic acid supplementation for a 6-month period. This timeframe only covers approximately two rounds of spermatogenesis and sperm maturation. With this limited window of exposure, we did not expect to see as many dramatic and consistent changes in sperm DNA methylation. Indeed, fewer altered DMCs were observed following folic acid supplementation and few neighboring sites were combined to create regions of differential methylation. Studying longer exposures to folic acid supplements and/or examining whether any alterations in the sperm methylome persist following the cessation of supplements, would allow us to determine the reversibility of any changes and whether perturbations affect stem cells, resulting in permanent alterations. Nonetheless, this modest exposure altered the sperm DNA methylome in a manner that could be detected, thereby demonstrating the sensitivity of both the sperm methylome and the human sperm capture panel.

As mentioned previously, a vast majority of the sites altered in methylation were found to be the dynamic sperm CpGs and would not have been detected with many of the commercially available techniques. Whether these dynamic sites are more likely to be affected following other types of exposures in adult men requires further study. Indeed, studies that have examined the effect of different environmental stressors and/or factors---such as smoking ([@c36]), cannabis use ([@c53]), obesity ([@c23]), phthalates ([@c65]), BPA ([@c62]), childhood abuse ([@c59]), and even exercise ([@c22])---have demonstrated alterations in human sperm DNA methylation. All but one of these studies ([@c62]) used different versions of Illumina®'s methylation array or RRBS. The use of the human sperm capture panel would allow the targeting of many of these same regions, with the added benefit of analyzing sites of dynamic methylation, at high coverage and not requiring full and costly assessment of the entire sperm DNA methylome. Examining how the risk of different environmental exposures affects the sperm DNA methylation is of great importance given that these germ cells can influence the health of future generations.

In addition to strengths of our study, there are several limitations. The greatest limitation is the small sample size of patients. Although in observational studies, large cohort sizes are expected, our motivation was to test the applicability of our human capture panel to experimentally detect previously studied alterations due to perturbations in one-carbon metabolism and the folic acid pathway. Although patient numbers in each of our experimental groups were low, we were able to obtain results similar to previous studies in animal models (*MTHFR* genotype effect) and from larger patient numbers (folic acid effects), demonstrating the suitability of our human sperm capture panel to detect alterations in sperm DNA methylation. Some patient characteristics that could affect the sperm DNA methylome, such as BMI, were not known for our participants, something that is worth following up in future studies using our sperm capture panel. Age may also affect the sperm DNA methylome and represents another factor that should be examined in more detail with our approach in a larger cohort of men. Another limitation of our study is the inability of bisulfite sequencing to distinguish between 5-methylcytosine ($5\text{mC}$) and 5-hydroxymethylcytosine ($5\text{hmC}$). $5\text{mC}$ can be actively demethylated through ten-eleven translocation mediated oxidation to $5\text{hmC}$ and has been found to be important in the epigenetic reprograming of germ cells in mouse and humans ([@c30]; [@c61]; [@c66]). Although $5\text{hmC}$ is found at several orders of magnitude less than $5\text{mC}$ in sperm, recent studies relying on immunofluorescence ([@c25]), enzyme-linked immunosorbent assay (ELISA) ([@c33]), and immunoprecipitation followed by sequencing ([@c67]) have found altered amounts of $5\text{hmC}$ in sperm due to semen quality, age, and exposures to bisphenol A, respectively. It would be interesting to determine the impact of different exposures on both $5\text{mC}$ and $5\text{hmC}$ levels through oxidative bisulfite sequencing ([@c9]), which can be amenable to capture sequencing.

Our pooled approach for developing customized tools for epigenome variability, in a tissue-targeted manner, addresses specific variation in the human sperm epigenome. With our human sperm methylation capture panel, we discovered differential DNA methylation following conditions affecting folate metabolism, most of which was found to be in novel dynamic sperm CpG sites. Our customized panel allows for accurate assessment of sperm DNA methylation profiles at single CpGs with an unprecedented coverage, targets putative environmentally sensitive sequences in human sperm and improves our ability to examine environmental impacts on DNA methylation in human sperm.
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